An analysis presented at the Society for Medical Decision Making’s 36th Annual North American Meeting suggests that it may be beneficial to routinely immunize patients with rheumatoid arthritis (RA) against herpes zoster (HZ).

Rheumatoid arthritis (RA) is a chronic, systemic inflammatory illness with significant potential for morbidity and disability. Although treatment options have significantly expanded in the past 15 years, we are still faced with patients who do not achieve full remission and have persistent symptoms.

With patient cost-sharing becoming an increasingly common strategy in managed care, the amalgamation of our economy and high drug costs can impact decisions made by patients in the name of cost-cutting.

The AIM FARTHER program developed at Geisinger Health System in Pennsylvania is a unique initiative designed to improve the quality of care for patients with rheumatoid arthritis (RA) and reduce costs.

Results from a recent prospective analysis indicated that the use of a prioritization tool for rheumatoid arthritis (RA) referrals improves access when rheumatologists are scarce

Inflammatory autoimmune conditions can affect different body systems, resulting in a variety of diseases involving the joints, skin, brain, and other organs.

A single-center study found the herpes zoster (HZ) vaccine was safe in patients taking biologics for rheumatoid arthritis (RA) and other arthritic disease.

Secukinumab, an interleukin (IL)-17A inhibitor, was found effective in pivotal phase 3 studies among patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA).

Systemic lupus erythematosus (SLE), often seen in women of childbearing age, is an autoimmune disease that affects multiple organ systems.